Free Newsletter
SEC accuses Merck exec of insider trading
Free newsletter via e-mail
Tools
In a civil suit filed in Philadelphia, the SEC accused James Self, 45, an executive director at Merck, of feeding his business school buddy and former hedge fund manager Stephen Goldfield, 46, the details of a 2007 Merck deal to buy drug firm MedImmune. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: